Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutasteride for AUR Relapse Prevention
NCT00421421Phase 4Terminated
- Sponsor
- GSK
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Dutasteride with Placebo (2 arms). Primary endpoint: Acute Urinary Retention (AUR) relapse rate at 24 weeks. Started Mar 2007; status: terminated.
02
Drugs
dutasteride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00421421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421421.